

Maria Ochoa de Olza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3566445/publications.pdf>

Version: 2024-02-01

21
papers

719
citations

933447

10
h-index

940533

16
g-index

21
all docs

21
docs citations

21
times ranked

1177
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. <i>Cancer Discovery</i> , 2022, 12, 108-133. | 9.4 | 165 |
| 2 | OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 460-472. | 7.0 | 48 |
| 3 | A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , 2021, 299, 109-119. | 7.3 | 54 |
| 4 | In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2533-2533. | 1.6 | 0 |
| 5 | A promising platform for predicting toxicity. <i>ELife</i> , 2021, 10, . | 6.0 | 3 |
| 6 | Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. <i>European Journal of Cancer</i> , 2021, 155, 168-178. | 2.8 | 1 |
| 7 | High versus low dose irradiation for tumor immune reprogramming. <i>Current Opinion in Biotechnology</i> , 2020, 65, 268-283. | 6.6 | 13 |
| 8 | <p>PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10251-10260. | 1.9 | 5 |
| 9 | Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes. , 2020, 8, e001155. | | 3 |
| 10 | Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. <i>Lancet Oncology</i> , The, 2020, 21, e419-e430. | 10.7 | 128 |
| 11 | A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-“PD-1 antibody, in patients with advanced solid tumors. , 2020, 8, e000530. | | 54 |
| 12 | Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?. <i>Clinical Cancer Research</i> , 2019, 25, 3210-3219. | 7.0 | 35 |
| 13 | A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. <i>Human Gene Therapy</i> , 2019, 30, 352-364. | 2.7 | 66 |
| 14 | A phase I trial of oncolytic adenovirus ICOVIR-5 administered intravenously to melanoma patients. <i>Human Gene Therapy Clinical Development</i> , 2018, , . | 3.1 | 3 |
| 15 | The expanding role of immunotherapy. <i>Cancer Treatment Reviews</i> , 2017, 54, 74-86. | 7.7 | 100 |
| 16 | Immuno-Oncology: The Third Paradigm in Early Drug Development. <i>Targeted Oncology</i> , 2017, 12, 125-138. | 3.6 | 22 |
| 17 | Molecular markers to predict response to selective fibroblast growth factor receptor inhibitors (FGFRinh) in patients (pts) with FGFR-amplified (amp) or mutated (mut) tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2581-2581. | 1.6 | 0 |
| 18 | Matching degree between PI3K/AKT/mTOR (PAM) pathway mutations (mut) and therapy (ttx) as predictor of clinical benefit (ClinBen) in early trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2572-2572. | 1.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 3060-3060. | 1.6 | 11 |
| 20 | The Personalization of Therapy: Molecular Profiling Technologies and Their Application. Seminars in Oncology, 2015, 42, 775-787. | 2.2 | 6 |
| 21 | Active surveillance before sequential targeted therapy in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, e15582-e15582. | 1.6 | 0 |